Regeneration initiating cells

• US 20060140913A1
• Filed: 07/29/2003
• Published: 06/29/2006
• Est. Priority Date: 07/29/2002
• Status: Active Grant

• Current Assignee: Robarts Research Institute
• Original Assignee: Asahi Kasei Kabushiki Kaisha, Robarts Research Institute
• Inventors: Bhatia, Mickie
• Granted Patent: US 7,527,968 B2
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 35/14 Blood; Artificial blood perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61K 35/51 Umbilical cord; Umbilical cord blood; Umbilical stem cells
• CPC Class Codes: A61P 5/48 of the pancreatic hormones

Abstract

Methods and compositions for treating hyperglycemia and pancreatic damage as well as stimulating the repair or regeneration of islet cells are disclosed.

Claims

1-11. -11. (canceled)

12. A pharmaceutical composition for treating or preventing pancreatic damage comprising regeneration initiating cells in admixture with a pharmaceutically acceptable diluent, excipient or carrier, wherein the regeneration initiating cells are present in an effective amount to treat or prevent pancreatic damage.

16. The pharmaceutical composition according to claim 12 wherein the regeneration initiating cells are derived from bone marrow, peripheral blood, umbilical cord blood or placenta.

17. The pharmaceutical composition according to claim 12 wherein the regeneration initiating cells have the surface marker c-kit.

18. The pharmaceutical composition according to claim 12 wherein the regeneration initiating cells have the surface markers c-kit and at least one marker selected from the group consisting of KDR, AC 133, CD34, Tie-1/2, Tek-1/2, VEGF-receptor families, CD31, and angiopoietin receptors.

19. The pharmaceutical composition according to claim 12 wherein the regeneration initiating cell is human.

13. A pharmaceutical composition for stimulating the regeneration or repair of damaged islet cells comprising regeneration initiating cells in admixture with a pharmaceutically acceptable diluent, excipient or carrier, wherein the regeneration initiating cells are present in an effective amount to stimulate the regeneration or repair of damaged islet cells.

14. A pharmaceutical composition for inducing the regeneration or repair of a damaged insulin secreting cell comprising a regeneration initiating cells in admixture with a pharmaceutically acceptable diluent, excipient or carrier, wherein the regeneration initiating cells are present in an effective amount to induce the regeneration or repair of a damaged insulin secreting cell.

15. A pharmaceutical composition for treating hyperglycemia comprising regeneration initiating cells in admixture with a pharmaceutically acceptable diluent, excipient or carrier, wherein the regeneration initiating cells are present in an effective amount to treat hyperglycemia.

20-22. -22. (canceled)

23. A method of detecting the presence of a regeneration initiation cell in a sample comprising:

(a) isolating low density mononuclear cells from the sample;

(b) transplanting the low density mononuclear cells into a recipient animal with tissue or organ damage; and

(c) determining whether or not the transplanted cells engraft the damage tissue or organ, wherein engraftment of the damaged tissue or organ indicates the presence of regeneration initiation cells in the sample.

24. The method according to claim 23 wherein the sample is selected from the group consisting of bone marrow, peripheral blood, umbilical cord blood and placenta.

25. The method according to claim 23 wherein the sample is from a human.

26. The method according to claim 23, wherein the recipient animal is a mouse.

27. The method according to claim 23 wherein the recipient animal has diabetes.

28. The method according to claim 23 wherein the tissue or organ is pancreas.

29. A method of treating or preventing pancreatic damage comprising administering an effective amount of isolated regeneration initiating cells to an animal in need thereof.

30. A method of stimulating the regeneration or repair of damaged islet cells comprising administering an effective amount of isolated regeneration initiating cells to an animal in need thereof.

31. A method of stimulating the regeneration or repair of damaged insulin secreting cells comprising administering an effective amount of a regeneration initiating cell to an animal in need thereof.

32. A method of treating hyperglycemia comprising administering an effective amount of a regeneration initiating cell to an animal in need thereof.

33. The method according to claim 32 wherein the regeneration initiating cells are derived from a source selected from the group consisting of bone marrow, peripheral blood, umbilical cord blood and placenta.

34. The method according to claim 33 wherein the regeneration initiating cell has the surface marker c-kit.

35. The method according to claim 33 wherein the regeneration initiating cell has the surface markers c-kit and at least one marker selected from the group consisting of KDR, AC133, CD34, Tie-1/2, Tek-1/2, VEGF-receptor families, CD31, and angiopoietin receptors.

36. The method according to claim 32 wherein the regeneration initiating cell is human.

37. The method according to claim 32 for the treatment of diabetes.

38. The method according to claim 37 wherein the diabetes is insulin dependent Type II diabetes.

39. The method according to claim 32 wherein the animal is a human.

40. The method according to claim 32 wherein the cells are low density mononuclear lymphocytes.